Hong Kong Taikuk (China) Group

Hong Kong Taikuk (China) Group is a private Hong Kong company that appears to operate primarily as a commercial and investment vehicle rather than as a drug developer. Publicly available evidence links the company to consumer health and nutraceutical commercialization in China through its 2022 joint venture with ChromaDex to market Tru Niagen and other Niagen-containing products. There is no clear evidence that Taikuk itself runs an internal biotech or pharmaceutical R&D pipeline, clinical programs, or proprietary therapeutic platform. Based on available records, the company is active and registered in Hong Kong, with historical evidence of a prior name change from Hong Kong Tinbon (China) Group. For biotech diligence purposes, it is best characterized as a health-related commercial partner with exposure to nutraceutical distribution rather than a clinical-stage life sciences company.